Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 1/2012

01-02-2012 | MEDICOPSYCHIATRIC DISORDERS (WJ KATON, SECTION EDITOR)

A Review of the Association Between Depression and Insulin Resistance: Pitfalls of Secondary Analyses or a Promising New Approach to Prevention of Type 2 Diabetes?

Authors: Naomi Silva, Evan Atlantis, Khalida Ismail

Published in: Current Psychiatry Reports | Issue 1/2012

Login to get access

Abstract

We review the validity of the evidence for an association between depression and the risk of insulin resistance (IR). We describe the potentially plausible biological and behavioral mechanisms that explain how depression increases the risk of IR and consequent overt diabetes. We have identified gaps in the literature to guide future research. Evidence for bidirectional associations between depression and IR is inconsistent. Results showing positive associations between depression and IR are derived from cross-sectional studies, whereas negative findings are typically reported in cohort studies. On the other hand, tentative trial evidence suggests that the effective treatment of depression can improve IR, and that lifestyle programs improve IR and reduce depressive symptoms. These emerging themes could lead to potential new multidisciplinary approaches to preventing diabetes.
Literature
1.
World Health Organization. The global burden of disease: 2004 Update. WHO Press; 2008.
2.
Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care. 2002;25(3):464–70.PubMedCrossRef
3.
Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130–9.PubMedCrossRef
4.
••Nouwen A, Nefs G, Caramlau I, et al. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes. Diabetes Care. 2011;34(3):752–762. This review shows that the prevalence of depression is similar in people with pre-diabetes compared with those with normal fasting plasma glucose and undiagnosed diabetes, but higher in people with known diabetes.PubMedCrossRef
5.
Knol MJ, Twisk JW, Beekman AT, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49(5):837–45.PubMedCrossRef
6.
Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383–90.PubMedCrossRef
7.
Lawlor DA, Smith GD, Ebrahim S. British Women’s Heart and Health study: association of insulin resistance with depression: cross sectional findings from the British Women’s Heart and Health study. BMJ. 2003;327(7428):1383–4.PubMedCrossRef
8.
Timonen M, Rajala U, Jokelainen J, et al. Depressive symptoms and insulin resistance in young adult males: results from the Northern Finland 1966 birth cohort. Mol Psychiatry. 2006;11(10):929–33.PubMedCrossRef
9.
Timonen M, Salmenkaita I, Jokelainen J, et al. Insulin resistance and depressive symptoms in young adult males: findings from Finnish military conscripts. Psychosom Med. 2007;69(8):723–8.PubMedCrossRef
10.
Adriaanse MC, Dekker JM, Nijpels G, et al. Associations between depressive symptoms and insulin resistance: the Hoorn study. Diabetologia. 2006;49(12):2874–7.PubMedCrossRef
11.
Pan A, Ye X, Franco OH, et al. Insulin resistance and depressive symptoms in middle-aged and elderly Chinese: findings from the Nutrition and Health of Aging Population in China Study. J Affect Disord. 2008;109(1–2):75–82.PubMedCrossRef
12.
Holt RI, Phillips DI, Jameson KA, et al. The relationship between depression and diabetes mellitus: findings from the Hertfordshire cohort study. Diabet Med. 2009;26(6):641–8.PubMedCrossRef
13.
Pearson S, Schmidt M, Patton G, et al. Depression and insulin resistance: cross sectional associations in young adults. Diabetes Care. 2010;33(5):1128–33.PubMedCrossRef
14.
Golden SH, Lee HB, Schreiner PJ, et al. Depression and type 2 diabetes mellitus: the multiethnic study of atherosclerosis. Psychosom Med. 2007;69(6):529–36.PubMedCrossRef
15.
Roos C, Lidfeldt J, Agardh CD, et al. Insulin resistance and self-rated symptoms of depression in Swedish women with risk factors for diabetes: the Women’s Health in the Lund Area study. Metab Clin Exp. 2007;56(6):825–9.PubMedCrossRef
16.
Shen Q, Bergquist-Beringer S, Sousa VD. Major depressive disorder and insulin resistance in nondiabetic young adults in the United States: the National Health and Nutrition Examination Survey, 1999–2002. Biological Research for Nursing 2010. [Epub ahead of print].
17.
Lawlor DA, Ben-Shlomo Y, Ebrahim S, et al. Insulin resistance and depressive symptoms in middle aged men: findings from the Caerphilly prospective cohort study. BMJ. 2005;330(7493):705–6.PubMedCrossRef
18.
Everson-Rose SA, Meyer PM, Powell LH, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care. 2004;27(12):2856–62.PubMedCrossRef
19.
Chiba M, Suzuki S, Hinokio Y, et al. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metab Clin Exp. 2000;49(9):1145–9.PubMedCrossRef
20.
Hung YJ, Hsieh CH, Chen YJ, et al. Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder. Clin Endocrinol. 2007;67(5):784–9.CrossRef
21.
Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000;49(10):1255–160.PubMedCrossRef
22.
Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol. 2005;21(3):129–37.PubMedCrossRef
23.
Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry. 2006;67(12):1856–61.PubMedCrossRef
24.
Chen YC, Lin WW, Chen YJ, et al. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators of Inflammation; 2010. [Epub 2010 May 18].
25.
Atlantis E, Lange K, Goldney RD, et al. Specific medical conditions associated with clinically significant depressive symptoms in men. Soc Psychiatry Psychiatr Epidemiol 2010.
26.
Barton DA, Dawood T, Lambert EA, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens. 2007;25:2117–24.PubMedCrossRef
27.
Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev. 2008;57:531–53.PubMedCrossRef
28.
Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J. 2008;29:1110-a–1117.CrossRef
29.
Champeri Wand GS, Malhotra SS, et al. Biological basis of depression in adults with diabetes. Curr Diabetes Rep. 2010;10(6):396–405.CrossRef
30.
Pizzi C, Mancini S, Angeloni L, et al. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther. 2009;86:527–32.PubMedCrossRef
31.
Buhl ES, Jensen TK, Jessen N, et al. Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats. Am J Physiol Endocrinol Metab. 2010;298:E920–9.PubMedCrossRef
32.
Danese A, Pariante CM, Caspi A, et al. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA. 2007;104(4):1319–24.PubMedCrossRef
33.
Ismail K, Sloggett A, De Stavola B. Do common mental disorders increase cigarette smoking? Results from five waves of a population-based panel cohort study. Am J Epidemiol. 2000;152(7):651–7.PubMedCrossRef
34.
•Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220–229. This systematic review showed for the first time bidirectional associations between obesity and depression, and provides support for the hypothesis that lifestyle behaviors (unhealthy eating and physical inactivity) mediate the association between depression and diabetes.PubMedCrossRef
35.
Patton GC, Carlin JB, Coffey C, et al. Depression, anxiety, and smoking initiation: a prospective study over 3 years. Am J Public Health. 1998;88:1518–22.PubMedCrossRef
36.
van Gool CH, Kempen GIJM, Penninx BWJH, et al. Relationship between changes in depressive symptoms and unhealthy lifestyles in late middle aged and older persons: results from the Longitudinal Aging Study Amsterdam. Age Ageing. 2003;32:81–7.PubMedCrossRef
37.
Patten SB, Williams JVA, Lavorato DH, Eliasziw M: A longitudinal community study of major depression and physical activity. General Hospital Psychiatry; 2009;31:571–575.
38.
Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry. 2003;60:817–26.PubMedCrossRef
39.
Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51:1356–67.PubMedCrossRef
40.
Drewnowski A. The real contribution of added sugars and fats to obesity. Epidemiol Rev. 2007;29:160–71.PubMedCrossRef
41.
Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24:451–63.PubMedCrossRef
42.
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623–34.CrossRef
43.
Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care. 2008;31:2398–403.PubMedCrossRef
44.
Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006;166:2314–21.PubMedCrossRef
45.
Roy-Byrne P, Craske MG, Sullivan G, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010;303:1921–8.PubMedCrossRef
46.
Gilbody S, Bower P, Whitty P. Costs and consequences of enhanced primary care for depression: systematic review of randomised economic evaluations. Br J Psychiatry. 2006;189:297–308.PubMedCrossRef
47.
Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363(27):2611–20.PubMedCrossRef
48.
Simon GE, Rohde P, Ludman EJ, et al. Association between change in depression and change in weight among women enrolled in weight loss treatment. Gen Hosp Psychiatry. 2010;32:583–9.PubMedCrossRef
49.
•Ye Z, Chen L, Yang Z, et al. Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS One. 2011;6:e21551. This systematic review shows significant treatment effects of fluoxetine on reducing weight, triglyceride, and glycated hemoglobin levels in obese people with type 2 diabetes mellitus, which should be taken into account in the pharmacologic management of depression in individuals with excess body weight and diabetes.PubMedCrossRef
50.
Metadata
Title
A Review of the Association Between Depression and Insulin Resistance: Pitfalls of Secondary Analyses or a Promising New Approach to Prevention of Type 2 Diabetes?
Authors
Naomi Silva
Evan Atlantis
Khalida Ismail
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Psychiatry Reports / Issue 1/2012
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-011-0245-8

Other articles of this Issue 1/2012

Current Psychiatry Reports 1/2012 Go to the issue

MEDICOPSYCHIATRIC DISORDERS (WJ KATON, SECTION EDITOR)

Depression and Mortality in End-Stage Renal Disease

MEDICOPSYCHIATRIC DISORDERS (WJ KATON, SECTION EDITOR)

Serious Psychological Distress and Diabetes: A Review of the Literature

MEDICOPSYCHIATRIC DISORDERS (WJ KATON, SECTION EDITOR)

Asthma and Suicide: Current Knowledge and Future Directions

PERSONALITY DISORDERS (H KOENIGSBERG, SECTION EDITOR)

Long-Term Outcomes in Borderline Psychopathology: Old Assumptions, Current Findings, and New Directions

PERSONALITY DISORDERS (H KOENIGSBERG, SECTION EDITOR)

Developmental Pathways to Borderline Personality Disorder

PERSONALITY DISORDERS (H KOENIGSBERG, SECTION EDITOR)

Aggression in Borderline Personality Disorder: Evidence for Increased Risk and Clinical Predictors